Voyageur Pharmaceuticals is pursing an innovative 'earth to bottle' model through its ownership of natural barium and iodine resources

To become a vertically integrated global leader in medical imaging contrast media by developing cost-effective and best in class products. We are experts in mineral mining and processing. Our ownership of natural barium and iodine resources within North America enables us to implement a strategy aimed at building a stable supply chain for imaging products critical for patient diagnosis. We have assembled a team of contrast media experts and world leading radiologists to drive our decision making for this important patient-led initiative, the starting point being several Health Canada licenses already approved for barium contrast media. Voyageur is now working with the FDA to register our products in the US market, whilst creating a drug dossier for the European and International markets. Our long term vision is to serve both the barium and iodine contrast media markets, from a fully integrated supply chain: “From The Earth To The Bottle”.

Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) announced its first commercial sale, marking the Canadian company’s transition into revenue-generating operations in the radiology contrast media sector.

The initial C$89,000 purchase order was placed by a leading Canadian radiology provider and includes the full suite of Voyageur’s Health Canada–approved barium contrast agents, the company said in a statement Wednesday.

First deliveries are scheduled to begin in August via the company’s manufacturing partner in Calgary.

“This sale marks the beginning of Voyageur’s commercial era,” said Brent Willis, Voyageur’s CEO. “It confirms market demand for our domestically produced contrast agents and sets the stage for accelerated revenue growth as we scale operations and distribution.”

Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) has announced the promotion of Ethan Mohan to executive vice president.

Mohan, who previously held the position of sales manager, has driven the company’s sales strategies and strategic partnerships, the company said on Tuesday. 

Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) has announced changes to its board of directors, which the company said aligns with its next phase of growth.

This includes the retirement of Ralph Hesje from the role of chairman.

Voyageur Pharmaceuticals CEO Brent Willis joined Steve Darling from Proactive to announce a significant milestone for the company: entering into a Letter of Intent (LOI) with a major multinational pharmaceutical company. This strategic collaboration is aimed at enhancing production efficiencies and expanding Voyageur’s project portfolio within the contrast media industry.

Willis explained that the proposed partnership is expected to accelerate Voyageur’s development of vertically integrated production for its suite of contrast media products. The collaboration would also enable the company to expedite its entry into new segments of the contrast media market, positioning Voyageur for faster progress across its operations.

Radiology contrast media use compounds like barium sulfate and iodinated organic compounds to improve radiographic visibility of the GI tract in X-ray and in computerized tomography (CT) clinical investigations. Iodine contrast agents are extensively used intravenously, for example, in angiography. A crucial aspect is the need for appropriate regulatory approvals in the US market. Due to vertical integration, Voyageur intends to be the most price-competitive producer.